2020
Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas
Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.Peer-Reviewed Original ResearchT-cell lymphomaAggressive T-cell lymphomaWeekly dosing scheduleMycosis fungoides/Sezary syndromeMF/SSWeekly dosingCell lymphomaDosing schedulesBrentuximab vedotinSezary syndromeGamma-delta T-cell lymphomaWeekly scheduleNK-T cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaAnaplastic large cell lymphomaCancer response rateIncidence of neuropathyWeekly x 3Prospective clinical trialsStem cell transplantAdult T-cell leukemiaLarge cell lymphomaT-cell leukemiaDose weeklyOutcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas
Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationMF/SSTime of transplantStem cell transplantationT-cell lymphomaMedian followCell transplantationCell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaGamma-delta T-cell lymphomaMF/SS patientsLong-term complete responseCutaneous T-cell lymphomaTotal skin electron beamRefractory mycosis fungoidesClinical complete remissionDisease-free survivalComplete remissionOverall survivalPartial responseSkin involvementComplete responseMycosis fungoidesSS patientsInsights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
Yumeen S, Girardi M. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma. The Yale Journal Of Biology And Medicine 2020, 93: 111-121. PMID: 32226341, PMCID: PMC7087059.Peer-Reviewed Original ResearchConceptsGenomic copy number alterationsSingle nucleotide variantsCutaneous T-cell lymphomaCellular underpinningsJAK-STAT activationT-cell lymphomaT lymphocytesCopy number alterationsCTCL cellsSeries of alterationsWhole-exome sequencingCell lymphomaApoptosis resistanceNucleotide variantsOncogenic behaviorPathophysiology of CTCLSkin-homing T lymphocytesT cell activationCell expansionNumber alterationsCTCL pathogenesisGenetic alterationsGenomic alterationsCell-mediated immunityTherapeutic discovery
2019
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells.
Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. Journal Of Visualized Experiments 2019 PMID: 31157760, DOI: 10.3791/59370.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaDendritic cellsCellular vaccinesClinical efficacyAnti-tumor T cell immunityVivo anti-tumor responsesMonocyte-derived dendritic cellsTumor cellsSyngeneic mouse tumor modelsImmunogenic dendritic cellsAnti-cancer immunityT cell immunityAnti-tumor responseHuman dendritic cellsT-cell lymphomaAnti-tumor effectsKey mechanistic driversApoptotic tumor cellsMouse tumor modelsCell immunitySafety profileCancer immunotherapyCell lymphomaMouse modelBlood samples
2018
BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition
Kim R, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Oncotarget 2018, 9: 29193-29207. PMID: 30018745, PMCID: PMC6044378, DOI: 10.18632/oncotarget.25670.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaCTCL cellsBCL2 inhibitionCell lymphomaAdvanced cutaneous T-cell lymphomaHDAC inhibitionSkin-homing T cellsPromising novel therapeutic strategyBET inhibitionNon-Hodgkin lymphomaPotential novel therapyCTCL cell linesDose-dependent decreaseNovel therapeutic strategiesHistone deacetylase inhibitionExtraterminal protein inhibitorSystemic therapyLymph nodesPeripheral bloodNovel therapiesT cellsTherapeutic strategiesCaspase-3/7 activationAdvanced stage
2016
Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells
Kibbi N, Sobolev O, Girardi M, Edelson RL. Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells. Transfusion And Apheresis Science 2016, 55: 146-152. PMID: 27317354, DOI: 10.1016/j.transci.2016.06.001.Peer-Reviewed Original ResearchConceptsCD8 T cell responsesCutaneous T-cell lymphomaT cell responsesCell responsesCD8 T cell populationsMonocyte-derived DCsAnti-tumor immunityT cell populationsT-cell lymphomaAntigen presenting cellsClass I major histocompatibilityCentral mechanistic roleMelanoma-associated proteinImmunotherapeutic managementHost diseaseAllograft rejectionPresenting cellsDendritic antigenImmunologic reactionsCell lymphomaMalignant cloneMajor histocompatibilityPathogenic clonesCell populationsAntigen
2015
Genomic landscape of cutaneous T cell lymphoma
Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic landscape of cutaneous T cell lymphoma. Nature Genetics 2015, 47: 1011-1019. PMID: 26192916, PMCID: PMC4552614, DOI: 10.1038/ng.3356.Peer-Reviewed Original Research
2014
Integrin‐driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy
Gonzalez AL, Berger CL, Remington J, Girardi M, Tigelaar RE, Edelson RL. Integrin‐driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy. Clinical & Experimental Immunology 2014, 175: 449-457. PMID: 24188174, PMCID: PMC3927905, DOI: 10.1111/cei.12231.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaDC differentiationHuman leucocyte antigen DDendritic antigen-presenting cellsPlasma proteinsAntigen-presenting cellsT-cell lymphomaECP efficacyHost diseaseClinical efficacySafety profileSelective immunizationCell lymphomaAntigen DCell treatmentMonocytesPhenotypic expressionEfficacyNovel mechanismECPDifferentiationCD83ImmunosuppressionCD86Fibronectin
2013
Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: Initiation via direct platelet signaling
Durazzo TS, Tigelaar RE, Filler R, Hayday A, Girardi M, Edelson RL. Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: Initiation via direct platelet signaling. Transfusion And Apheresis Science 2013, 50: 370-378. PMID: 24360371, PMCID: PMC4167725, DOI: 10.1016/j.transci.2013.11.008.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaExtracorporeal photochemotherapyDendritic cellsDendritic cell maturationT-cell lymphomaInduction of monocytesEvidence of inductionPost-capillary venulesDC maturationCell lymphomaClinical actionsCell maturationPlatelet signalingMonocytesPhotochemotherapyReceptor-ligand interactionsNovel mechanismInductionPhysiological inductionMaturationPrevious studiesLymphomaTherapyVenules
2008
FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial
Kuo PH, Carlson KR, Christensen I, Girardi M, Heald PW. FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. Molecular Imaging And Biology 2008, 10: 306-314. PMID: 18665425, DOI: 10.1007/s11307-008-0161-4.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaFDG PET/CTPhase II trialParticular positron emission tomographyT-cell lymphomaII trialNodal diseaseInitial PET/CT scanPET/CT scansEarly clinical trialsEvaluation of responseHistone deacetylase inhibitorsAlters gene transcriptionPositron emission tomographyFDG uptakeCutaneous lesionsFDG-PETPrognostic valueFuture trialsClinical trialsConclusionFurther studiesCell lymphomaCT scanDeacetylase inhibitorsHDAC inhibitorsCutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities.
Berger CL, Heald P, Girardi M, Edelson RL. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. Giornale Italiano Di Dermatologia E Venereologia 2008, 143: 43-54. PMID: 18833050.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAnimalsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsApoptosisBexaroteneClone CellsCytokinesDendritic CellsDiphtheria ToxinGene Expression Regulation, NeoplasticHumansImmunophenotypingInterleukin-2Lymphoma, T-Cell, CutaneousMiceNeoplastic Stem CellsPhotopheresisPUVA TherapyRecombinant Fusion ProteinsTetrahydronaphthalenesT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryConceptsCutaneous T-cell lymphomaSheep red blood cellsT-cell lymphomaNew therapeutic approachesBasic science techniquesRed blood cellsClinical featuresTherapeutic optionsT lymphocytesCell lymphomaTherapeutic approachesClinical practiceImmune systemMalignant cellsTherapeutic opportunitiesBlood cellsPatientsImmunobiologyDiseaseMolecular demonstrationCurrent understandingCellsLymphomaLymphocytesImmunology
2006
Transimmunization for cutaneous T cell lymphoma: A phase I study
Girardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: A phase I study. Leukemia & Lymphoma 2006, 47: 1495-1503. PMID: 16966259, DOI: 10.1080/10428190600581419.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaCTCL patientsCell lymphomaMalignant cellsCD8 T cell poolPhase I clinical studyT cell poolSignificant mean reductionElectron beam therapyInfiltrative lesionsClinical studiesDendritic antigenBlood monocytesTransimmunizationMean reductionTumor loadingPatientsMonoclonal antibodiesMalignant leukocytesMinimal toxicityBeam therapyPhase ICell poolVivo contact
2002
Transimmunization, a novel approach for tumor immunotherapy
Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. Transfusion And Apheresis Science 2002, 26: 205-216. PMID: 12126207, DOI: 10.1016/s1473-0502(02)00014-9.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaImmune responseTumor antigensPotent antigen presenting cellsAnti-tumor immune responseExtracorporeal photopheresis (ECP) treatmentDendritic cell immunotherapyT-cell lymphomaAntigen presenting cellsPeripheral blood monocytesApoptotic tumor cellsApoptotic CTCL cellsPhotopheresis treatmentRejection episodesHost diseaseOvernight incubation periodTumor epitopesImmature DCsCell immunotherapyTumor immunotherapyAutoimmune diseasesDC differentiationInflammatory cytokinesPresenting cellsCell lymphomaEfficient Tumor Antigen Loading of Dendritic Antigen Presenting Cells by Transimmunization
Girardi M, Berger C, Hanlon D, Edelson RL. Efficient Tumor Antigen Loading of Dendritic Antigen Presenting Cells by Transimmunization. Technology In Cancer Research & Treatment 2002, 1: 65-69. PMID: 12614179, DOI: 10.1177/153303460200100109.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMalignant T cellsT cellsTumor antigen loadingAnti-tumor immunityManagement of patientsT-cell lymphomaAntigen presenting cellsDendritic cell differentiationDendritic cellsSelective immunotherapyPresenting cellsOnly FDATumor antigensCell lymphomaAntigen loadingTumor cellsKey cellular eventsTransimmunizationImmunotherapyPatientsCancerRecent findingsEfficient phagocytosisCells
2001
Extracorporeal Photochemoimmunotherapy in Cutaneous T Cell Lymphomas
KNOBLER R, GIRARDI M. Extracorporeal Photochemoimmunotherapy in Cutaneous T Cell Lymphomas. Annals Of The New York Academy Of Sciences 2001, 941: 123-138. PMID: 11594566, DOI: 10.1111/j.1749-6632.2001.tb03716.x.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT cell clonesAutoreactive T cell clonesT-cell lymphomaCell clonesCell lymphomaDisease-causing T cellsPathogenic T cell clonesT cell-mediated disordersClass I Major Histocompatibility Complex PresentationClonotypic T cell receptorCell-mediated disordersTumor-specific antigensMajor histocompatibility complex presentationT cell receptorTypes of cancerUnique antigenic determinantsECP efficacyHost diseaseAllograft rejectionConversion of monocytesSelective immunotherapyClinical trialsFunctional DCsDendritic antigenThe Clonotypic T Cell Receptor Is a Source of Tumor‐associated Antigens in Cutaneous T Cell Lymphoma
BERGER C, LONGLEY J, HANLON D, GIRARDI M, EDELSON R. The Clonotypic T Cell Receptor Is a Source of Tumor‐associated Antigens in Cutaneous T Cell Lymphoma. Annals Of The New York Academy Of Sciences 2001, 941: 106-122. PMID: 11594564, DOI: 10.1111/j.1749-6632.2001.tb03715.x.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsAntigens, NeoplasmCancer VaccinesCD8-Positive T-LymphocytesCell LineCells, CulturedHumansHybridomasImmunoglobulin IdiotypesLymphocyte ActivationLymphoma, T-Cell, CutaneousMiceNeoplasm TransplantationPeptidesReceptors, Antigen, T-CellSkin NeoplasmsSurvival RateT-Lymphocytes, CytotoxicTransfectionConceptsCutaneous T-cell lymphomaT-cell lymphomaT cell receptorClonotypic T cell receptorCell lymphomaAutologous CD8 T cellsCD8 T cell linesCell receptorBeta chainCD8 T cell recognitionImmunogenic tumor peptidesCD8 T cellsCell surface TCR expressionClass I MHC moleculesSource of tumorsT cell recognitionT-cell malignanciesTCR beta chainI MHC moleculesT cell linesTCR epitopesTumor epitopesDendritic cellsSurface TCR expressionCancer vaccines
1999
Extracorporeal photochemotherapy in human and murine graft-versus-host disease
Girardi M, McNiff J, Heald P. Extracorporeal photochemotherapy in human and murine graft-versus-host disease. Journal Of Dermatological Science 1999, 19: 106-113. PMID: 10098701, DOI: 10.1016/s0923-1811(98)00066-8.Peer-Reviewed Original Research